TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00100750
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00100750
Drug: Tipifarnib
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT03933631
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
Study: NCT03933631
Drug: Ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin Drops
Study: NCT04739345
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg of pentoxifylline orally TID with the standard COVID-19 protocol of the Egyptian Ministry of Health
Study: NCT00467467
Drug: Alfuzosin Hydrochloride
Normalized name: Alfuzosin Hydrochloride
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01642667
Drug: Prourokinase
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
Study: NCT02572687
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02241772
Drug: TA-8995
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01063881
Drug: Dapoxetine
Normalized name: dapoxetine
DrugBank: Dapoxetine (DB04884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
Study: NCT00145847
Drug: Naltrexone or Placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone or Placebo 50 mg per day
Study: NCT04452370
Drug: oral etoposide + anlotinib
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: anlotinib 12mg qd, d1-14，21days/cycle oral etoposide 75mg qd，d1-10，21days/cycle
Study: NCT01526746
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg capsule, once
Study: NCT01526746
Drug: Tasimelteon
Normalized name: Tasimelteon
DrugBank: Tasimelteon (DB09071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg, once
Study: NCT00537303
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
Study: NCT00537303
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
Study: NCT04168138
Drug: rhTPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)\>20\*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet\>50\*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
Study: NCT03325803
Drug: lidocaine/prilocaine (5%) application
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study: NCT04088292
Drug: Alteplase 20 Mg Powder for Solution for Injection Vial
Normalized name: Alteplase 20 mg powder for solution for injection vial
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
Study: NCT04044287
Drug: 200 micrograms of misoprostol
Normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
Study: NCT01029873
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
Study: NCT00537303
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
Study: NCT00000114
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000114
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00128050
Drug: rFactor VIIa (Eptacog alfa, NovoNordisk)
Normalized name: factor VIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
Study: NCT00128050
Drug: rFVIIa
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
Study: NCT03262038
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
Study: NCT01584297
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
Study: NCT04217057
Drug: 64Cu-DOTA-ECL1i
Normalized name: 64Cu-dotatate
DrugBank: Copper oxodotreotide Cu-64 (DB15873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be produced by the Cyclotron Facility at Washington University School of Medicine
Study: NCT05474716
Drug: Brimonidine tartrate 0.2% ophthalmic solution
Normalized name: Brimonidine Tartrate 0.2% Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical Brimonidine tartrate 0.2% bid ophthalmic solution. A selective alpha 2 adrenergic agonist with ocular hypotensive and neuroprotective properties used in glaucoma and ocular hypertension.
Study: NCT03944876
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Study: NCT02635672
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV fixed dose once every 3 weeks of a 21 day cycle
Study: NCT02573896
Drug: Dinutuximab
Normalized name: Dinutuximab
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 17.5 mg/m2/day of dinutuximab will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
Study: NCT02573896
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
Study: NCT02390635
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00545948
Drug: Vinorelbine followed by Cisplatin
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
Study: NCT00545948
Drug: Pemetrexed followed by Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
Study: NCT00558493
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: clevudine 30 mg qd for 24 seeks
Study: NCT03997734
Drug: AB001
Normalized name: Immunoglobulin g1, anti-(human programmed death-ligand 1) (human monoclonal zkab001 .gamma.1-chain), disulfide with human monoclonal zkab001 .lambda.-chain, dimer
DrugBank: Socazolimab (DB18845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and repeated dosing
Study: NCT03997734
Drug: oral capsule
Normalized name: Oral Capsule
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose
Study: NCT03997734
Drug: positive comparative patch
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and repeated dosing
Study: NCT01216085
Drug: high-dose imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
Study: NCT00265642
Drug: Irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet of 150 mg/d during 2 years
Study: NCT00641212
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00883909
Drug: dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A follow-up study in adult male subjects who have received investigational product
Study: NCT04256018
Drug: Mogamulizumab
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.
Study: NCT01523431
Drug: Irinotecan Injection [Camptosar]
Normalized name: irinotecan Injection [Camptosar]
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 \*1/\*1 or heterozygous UGT1A1\*1/\*28 or \*1/\*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1\*28/\*28, \*6/\*6 or \*28/\*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
Study: NCT01523431
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The 5-FU dosage will remain the standard.
Study: NCT01136967
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
Study: NCT03326921
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00003008
Drug: indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003008
Drug: nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003008
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003008
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00003008
Drug: saquinavir mesylate
Normalized name: Saquinavir Mesylate
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01505426
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral, concomitant use
Study: NCT01791296
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
Study: NCT00992394
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept 50 mg once weekly as requested.
Study: NCT00992394
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: etanercept 25 mg or 50 mg as requested.
Study: NCT00816673
Drug: Circadin
Normalized name: ZINC OXIDE 173 mg in 1 mL TOPICAL CREAM [Circadia Circa-Shield Mineral Sunscreen SPF 30]
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
Study: NCT04082442
Drug: Evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 420 mg evolocumab.
Study: NCT00226044
Drug: Omeprazole rectally 1mg/kg
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 1 mg/kg rectally administered omeprazole.
Study: NCT00523666
Drug: Galantamine (Reminyl®)
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg - 24mg
Study: NCT00523666
Drug: Placebo/Galantamine (Reminyl®)
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg
Study: NCT00863460
Drug: intensive chemotherapy and hematopoietic stem cell rescue
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive chemotherapy and hematopoietic stem cell rescue
Study: NCT00758043
Drug: telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 750 mg every 8 hours (q8h) for 12 weeks
Study: NCT00758043
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
Study: NCT03957057
Drug: Iron Carboxymaltose
Normalized name: Iron carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous iron carboxymaltose application
Study: NCT03957057
Drug: Iron Isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inravenous iron isomaltoside application
Study: NCT03957057
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate application
Study: NCT02834442
Drug: MT-7117
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00353015
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
Study: NCT00353015
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
Study: NCT00601016
Drug: Imiquimod 5% cream
Normalized name: IMIQUIMOD 5% CREAM,TOP,PKT,0.25GM
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
Study: NCT00344669
Drug: Albendazole 400 mg, given 6 monthly
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04359680
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 600 mg administered orally twice daily for six weeks
Study: NCT00520572
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00661154
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-12microCi IV injection
Study: NCT00960856
Drug: Fenofibric Acid 105 mg Tablet
Normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
Study: NCT00960856
Drug: Fenofibric Acid 105 mg Tablet
Normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
Study: NCT00960856
Drug: Fenofibric Acid 105 mg Tablet
Normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
Study: NCT00960856
Drug: Fenofibric Acid 105 mg Tablet
Normalized name: fenofibrate
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 105 mg tablet administered after an overnight fast of at least 10 hours.
Study: NCT00409227
Drug: Alpha blocker-alfuzosin
Normalized name: ALPHA BLOCKERS/RELATED
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P.O. alfuzosin 10 mg once a day
Study: NCT00660959
Drug: lixivaptan
Normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT00360100
Drug: Zmax
Normalized name: Zmax
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00374985
Drug: Docetaxel, Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: weekly doses
Study: NCT01812018
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
Study: NCT01812018
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
Study: NCT01812018
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
Study: NCT00985192
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00403065
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01330524
Drug: Avastin and Triamcinolone
Normalized name: Avastin
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
Study: NCT04957927
Drug: Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
Normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Effectiveness of Montelukast Versus Intranasal Fluticasone Propionate in the Management of Allergic Rhinitis Among Children 02 to 05 Years of Age
Study: NCT02913859
Drug: Hormonal therapy (LHRH agonist and/or antiandrogens)
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: life-long hormonal therapy (LHRH agonist and/or antiandrogens)
Study: NCT02913573
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
Study: NCT00558480
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
Study: NCT00558480
Drug: Vitamin A placebo
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A placebo at enrollment, 3 and 6 months
Study: NCT00555373
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~2. Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours).
Study: NCT00506311
Drug: Fibrin Sealant
Normalized name: FIBRIN SEALANT
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisseel applied externally to the dissected groin area.
Study: NCT02224079
Drug: BIIB 722 CL
Normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04189757
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00432991
Drug: Ephedrine [Synonyms: Ephedra, Ephedrinum]
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg, IM (in the muscle), one time